Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
30 mei 2008 - 17:43
Statutaire naam
Crucell N.V.
Titel
Crucell 2008 Annual General Meeting of Shareholders
Bericht
2007 Financial Statements Adopted; All Resolutions Approved
Leiden, The Netherlands (May 30, 2008) – Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that the Annual General Meeting of Shareholders (AGM) held today in Leiden adopted the 2007 financial statements. In addition, the AGM approved the resignation of Mr. Dominik Koechlin as a member of the Supervisory Board and has appointed Mr. Steve Davis as member of the Supervisory Board. Dr. Cees de Jong was appointed as a member of Crucell’s Board of Management.
The shareholders of Crucell were represented in person, by proxy voting, or by voting instruction, representing a total of 23% of the total issued share capital entitled to vote.
The shareholders approved the resignation of Mr. Dominik Koechlin as a member of the Supervisory Board, effectively today. In addition the shareholders appointed Mr. Steve Davis as member of the Supervisory Board. The appointment is for a term of four years, until 2012.
As a member of the Board of Management the shareholders appointed Dr. Cees de Jong for a term of four years. The other members of the Board of Management, Dr. Ronald Brus, Mr. Leonard Kruimer and Dr. Jaap Goudsmit were re-appointed for a term of four years by Crucell’s shareholders.
Furthermore the AGM approved the 2007 financial statements and all other resolutions.
At the meeting Ronald Brus, CEO and Leon Kruimer, CFO discussed Crucell’s 2007 results, reiterated the outlook for 2008 , and shared with the shareholders their view on the business and strategy of the company. The presentation of the AGM is available at the company’s website www.crucell.com.
Datum laatste update: 11 januari 2026